In one paragraphArticle in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Marina Gómez-RoselCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0001-8816-9844 Laura Rubio-PérezCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-2877-6092 Ivana ZagoracCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-7135-8283 Carmen Domínguez-AlonsoCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-0446-9629 Laura Díez-AlonsoCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-9545-6910 Oana HangiuCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-2641-8531 Rocío NavarroDepartment of Antibody Engineering, Leadartis SL, QUBE Technology Park, Tres Cantos, Madrid, Spain.ORCID 0000-0002-0083-7711 Raúl Torres-RuízMolecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Sandra Rodríguez-PeralesMolecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Marta CompteDepartment of Antibody Engineering, Leadartis SL, QUBE Technology Park, Tres Cantos, Madrid, Spain.ORCID 0000-0002-7138-9266 Luis Álvarez-VallinaCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0003-3053-6757 Belén BlancoCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0001-5085-7756 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (
Indexed as
Antibodies, BispecificAntigens, CD19B7-H1 AntigenImmunotherapy, AdoptiveT-LymphocytesTumor Necrosis Factor Receptor Superfamily, Member 9AnimalsCell Line, TumorFemaleHumansMiceXenograft Model Antitumor AssaysAntibodies, BispecificAntigens, CD19B7-H1 AntigenCD19 molecule, humanCD274 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 94-1BB costimulationbispecific antibodiesPD−1/PD-L1 blockersSTAb-T cells
Identifiers
PMID41139953
PMCPMC12562732
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390